115 related articles for article (PubMed ID: 16866906)
1. Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease.
Laskowitz DT; Fillit H; Yeung N; Toku K; Vitek MP
Acta Neurol Scand Suppl; 2006; 185():15-20. PubMed ID: 16866906
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury.
Lynch JR; Wang H; Mace B; Leinenweber S; Warner DS; Bennett ER; Vitek MP; McKenna S; Laskowitz DT
Exp Neurol; 2005 Mar; 192(1):109-16. PubMed ID: 15698624
[TBL] [Abstract][Full Text] [Related]
3. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity.
Guo L; LaDu MJ; Van Eldik LJ
J Mol Neurosci; 2004; 23(3):205-12. PubMed ID: 15181248
[TBL] [Abstract][Full Text] [Related]
4. An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction.
Wang H; Durham L; Dawson H; Song P; Warner DS; Sullivan PM; Vitek MP; Laskowitz DT
Neuroscience; 2007 Feb; 144(4):1324-33. PubMed ID: 17187933
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses.
LaDu MJ; Shah JA; Reardon CA; Getz GS; Bu G; Hu J; Guo L; Van Eldik LJ
Neurochem Int; 2001; 39(5-6):427-34. PubMed ID: 11578778
[TBL] [Abstract][Full Text] [Related]
6. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.
Bachmeier C; Paris D; Beaulieu-Abdelahad D; Mouzon B; Mullan M; Crawford F
Neurodegener Dis; 2013; 11(1):13-21. PubMed ID: 22572854
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.
Laskowitz DT; Vitek MP
Pharmacogenomics; 2007 Aug; 8(8):959-69. PubMed ID: 17716229
[TBL] [Abstract][Full Text] [Related]
8. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response.
Lynch JR; Tang W; Wang H; Vitek MP; Bennett ER; Sullivan PM; Warner DS; Laskowitz DT
J Biol Chem; 2003 Dec; 278(49):48529-33. PubMed ID: 14507923
[TBL] [Abstract][Full Text] [Related]
9. ApoE deficiency compromises the blood brain barrier especially after injury.
Methia N; André P; Hafezi-Moghadam A; Economopoulos M; Thomas KL; Wagner DD
Mol Med; 2001 Dec; 7(12):810-5. PubMed ID: 11844869
[TBL] [Abstract][Full Text] [Related]
10. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.
Martiskainen H; Haapasalo A; Kurkinen KM; Pihlajamäki J; Soininen H; Hiltunen M
Expert Opin Ther Targets; 2013 Jul; 17(7):781-94. PubMed ID: 23573918
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides.
Laskowitz DT; Thekdi AD; Thekdi SD; Han SK; Myers JK; Pizzo SV; Bennett ER
Exp Neurol; 2001 Jan; 167(1):74-85. PubMed ID: 11161595
[TBL] [Abstract][Full Text] [Related]
12. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia.
Horsburgh K; McCulloch J; Nilsen M; Roses AD; Nicoll JA
Eur J Neurosci; 2000 Dec; 12(12):4309-17. PubMed ID: 11122341
[TBL] [Abstract][Full Text] [Related]
13. Isoform-specific proteolysis of apolipoprotein-E in the brain.
Elliott DA; Tsoi K; Holinkova S; Chan SL; Kim WS; Halliday GM; Rye KA; Garner B
Neurobiol Aging; 2011 Feb; 32(2):257-71. PubMed ID: 19278755
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice.
Sheng H; Laskowitz DT; Bennett E; Schmechel DE; Bart RD; Saunders AM; Pearlstein RD; Roses AD; Warner DS
J Cereb Blood Flow Metab; 1998 Apr; 18(4):361-6. PubMed ID: 9538900
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE; Johanson CE
J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
[TBL] [Abstract][Full Text] [Related]
16. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice.
Xu PT; Schmechel D; Rothrock-Christian T; Burkhart DS; Qiu HL; Popko B; Sullivan P; Maeda N; Saunders AM; Roses AD; Gilbert JR
Neurobiol Dis; 1996; 3(3):229-45. PubMed ID: 8980023
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.
Christensen DJ; Ohkubo N; Oddo J; Van Kanegan MJ; Neil J; Li F; Colton CA; Vitek MP
J Immunol; 2011 Feb; 186(4):2535-42. PubMed ID: 21289314
[TBL] [Abstract][Full Text] [Related]
18. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E and the CNS response to injury.
Laskowitz DT; Horsburgh K; Roses AD
J Cereb Blood Flow Metab; 1998 May; 18(5):465-71. PubMed ID: 9591838
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E receptors and amyloid expression are modulated in an apolipoprotein E-dependent fashion in response to hippocampal deafferentation in rodent.
Petit-Turcotte C; Aumont N; Blain JF; Poirier J
Neuroscience; 2007 Nov; 150(1):58-63. PubMed ID: 17935896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
